Posts

The top pharma companies in 2021 continued to be engaged in creating vaccines and therapeutics, and the investments in R&D led to greater revenue and earnings.

For all its forays elsewhere, diabetes remains the bedrock of Lilly’s business – and, if the Mounjaro launch goes as hoped, will continue to be so for a long time to come.

Eli Lilly and Co. said on Thursday the U.S. Food and Drug Administration (FDA) had agreed to a quick review of its diabetes drug Mounjaro to treat obesity, months after a study showed it helped people lose more than 20% of their weight.

Today’s promising results from Eisai and Biogen’s Alzheimer’s drug trial have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.

The U.S. Equal Employment Opportunity Commission filed a lawsuit Monday against Eli Lilly and Co. alleging the company refused to hire older workers for sales representative positions.

AstraZeneca’s blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalization and death in people with all types of heart failure, according to study data released on Saturday, opening the door to a substantial increase in patients who could benefit.

Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their pricing power even as Congress moves to cut the $500 billion-plus annual bill for prescription drugs in the United States.

While the economy expands and contracts, the biopharma industry follows, and many life science companies are announcing both layoffs and expansions.

Global pharma giant Sanofi and Chinese company Innovent Biologics have penned a strategic partnership to develop and commercialize innovative treatments for patients with hard-to-treat cancers in China.

MiroBio and Gilead believe they can offer new, best-in-class assets to patients beset by different autoimmune diseases. The deal includes MiroBio’s lead investigational candidate, MB272, a selective agonist of T, B and dendritic cells that aims to inhibit or blunt activation and suppress an inflammatory immune response.